Adaptimmune Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Adaptimmune Therapeutics yıllık ortalama 13.1% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 36.2% annual. Gelirler yılda ortalama 47.9% oranında büyüyor .
Anahtar bilgiler
13.12%
Kazanç büyüme oranı
24.70%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | 17.04% |
| Gelir büyüme oranı | 47.87% |
| Özkaynak getirisi | -244.01% |
| Net Marj | -1,316.78% |
| Son Kazanç Güncellemesi | 31 Dec 2025 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • Feb 11
ADAP.Y: Executive Transition And Deregistration Will Support Future Upside Potential
Analysts have adjusted their price target on Adaptimmune Therapeutics to $1.50, keeping it aligned with their fair value estimate as they factor in an updated discount rate of 13.43%, steady high revenue growth assumptions near 46.25%, a slightly lower projected profit margin close to 16.05%, and a marginally higher future P/E expectation near 19.36. What's in the News Adaptimmune Therapeutics plans executive changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of Adrian Rawcliffe in connection with a company restructuring (Key Developments).Anlatı Güncellemesi • Jan 26
ADAP.Y: Leadership Restructuring And Deregistration Will Set Up Future Upside Potential
Analysts have trimmed their price target on Adaptimmune Therapeutics to US$1.50 from US$1.50, reflecting updated assumptions around profit margin and future P/E, while keeping their fair value view unchanged. What's in the News Adaptimmune Therapeutics plans leadership changes effective November 14, 2025, with Christopher Hill moving from Chief Financial Officer to Chief Executive Officer and joining the Board, following the departure of former CEO Adrian Rawcliffe in connection with a company restructuring (Key Developments).Anlatı Güncellemesi • Jan 12
ADAP.Y: Leadership Transition And Deregistration Will Shape Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have kept their price target for Adaptimmune Therapeutics broadly steady at around $1.50 per share. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E that remain closely aligned with prior estimates.Anlatı Güncellemesi • Dec 16
ADAP.Y: Leadership And Listing Changes Will Drive Future Upside Potential
Narrative Update on Adaptimmune Therapeutics Analysts have modestly increased their price target on Adaptimmune Therapeutics by approximately 3 percent to about 1.50 dollars per share, citing slightly stronger expected revenue growth and a marginally lower future price to earnings multiple in their updated models. What's in the News Chief Financial Officer Chris Hill has been appointed Chief Executive Officer and Director, succeeding long serving executive Adrian Rawcliffe as part of a broader company restructuring, while temporarily retaining his CFO role (company announcement).Anlatı Güncellemesi • Dec 02
ADAP.Y: Leadership Transition And Deregistration Will Drive Further Upside Potential
Analysts have maintained their price target for Adaptimmune Therapeutics at $1.50. Modest improvements in profitability and valuation ratios are balanced by steady expectations for growth and risk.Anlatı Güncellemesi • Nov 18
ADAP.Y: Voluntary SEC Deregistration and Index Removals Will Unlock Future Value
Analysts have raised their price target for Adaptimmune Therapeutics from $0.98 to $1.50. This change reflects updated expectations for valuation and revised future earnings metrics.Anlatı Güncellemesi • Nov 03
ADAP.Y: Compliance Efforts Will Overcome Index Removal To Drive Recovery
Analysts have raised the price target for Adaptimmune Therapeutics from $0.64 to $0.98 per share. This change reflects increased optimism on future revenue growth and profit margins, despite a slightly higher discount rate.Anlatı Güncellemesi • Aug 22
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Analysts have lowered their price target for Adaptimmune Therapeutics, citing solvency concerns, ongoing strategic uncertainty, and a lack of near-term catalysts, resulting in a revised fair value from $0.714 to $0.638. Analyst Commentary Bearish analysts cite significant solvency and sustainability concerns, questioning whether the company has sufficient financial resources to navigate near-term challenges.Anlatı Güncellemesi • Aug 07
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Despite a modestly improved revenue growth outlook and a significantly lower forward P/E, consensus analyst sentiment has worsened, leading to a marked price target reduction from $0.96 to $0.714. What's in the News Adaptimmune Therapeutics reached a settlement with MD Anderson Cancer Center to resolve litigation related to a previous strategic alliance, with all claims to be dismissed upon payment.
Yeni Anlatı • Apr 04
TCELRA And Lete-Cel Rollout Will Create Operational Efficiencies
Rapid treatment network expansion and successful TECELRA launch are driving significant future revenue growth and patient access.Analiz Makalesi • Mar 11
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders that were waiting for something to happen have been dealt a...Analiz Makalesi • Jan 01
Investors Don't See Light At End Of Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Tunnel And Push Stock Down 26%
To the annoyance of some shareholders, Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares are down a considerable 26...Analiz Makalesi • Dec 15
Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Unfortunately for some shareholders, the Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) share price has dived 32% in the...Analiz Makalesi • Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders won't be pleased to see that the share price has had a very...Seeking Alpha • Sep 12
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Summary Adaptimmune received FDA approval for Tecelra, with a 39% response rate in synovial sarcoma and a boxed warning for cytokine release syndrome. The U.S. population eligible for Tecelra is small, approximately 100-400 patients, based on various eligibility factors. The collaboration with Galapagos provides $70 million upfront and potential milestone payments up to $465 million, expanding the development of uza-cel in solid tumors. Adaptimmune’s Q2 2024 revenue jumped due to deferred revenue from the terminated Genentech collaboration, resulting in a $69.5 million net profit. Given the limited market and logistical complexities, the likelihood of peak revenue exceeding $200 million is low, presenting high investment risk. Read the full article on Seeking AlphaSeeking Alpha • Jul 03
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Summary Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further. Read the full article on Seeking AlphaSeeking Alpha • Apr 26
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Summary Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have retraced a considerable 29% in the last month, reversing a...Analiz Makalesi • Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shares have continued their recent momentum with a 107% gain in the last...Seeking Alpha • Feb 02
Adaptimmune: Drug Approval Now Imminent?
Summary Adaptimmune's BLA for their T-cell therapy in soft tissue sarcomas has been accepted for review by the FDA. The company's lead candidate, Afami-cel, has shown promising results in synovial sarcoma, with a PDUFA date set for August 4, 2024. Adaptimmune's cash position is low, but expected milestone payments from their collaboration with Genentech may extend their cash runway. Read the full article on Seeking AlphaAnaliz Makalesi • Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders are no doubt pleased to see that the share price has bounced...Analiz Makalesi • Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...Analiz Makalesi • Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Shareholders in Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) may be thrilled to learn that the analysts have just...Analiz Makalesi • Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analiz Makalesi • Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 20
Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Summary Adaptimmune Therapeutics plans to file a BLA this year. Despite that, the stock remains depressed. Their cash position is difficult as well.Analiz Makalesi • Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Adaptimmune Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Dec 25 | 6 | -78 | 36 | 48 |
| 30 Jun 25 | 65 | -170 | 84 | 0 |
| 31 Mar 25 | 180 | -70 | 83 | 0 |
| 31 Dec 24 | 178 | -71 | 81 | 0 |
| 30 Sep 24 | 175 | -45 | 70 | 0 |
| 30 Jun 24 | 141 | -72 | 72 | 0 |
| 31 Mar 24 | 18 | -163 | 70 | 0 |
| 31 Dec 23 | 60 | -114 | 64 | 0 |
| 30 Sep 23 | 71 | -95 | 68 | -105 |
| 30 Jun 23 | 71 | -91 | 61 | 0 |
| 31 Mar 23 | 71 | -114 | 59 | 0 |
| 31 Dec 22 | 27 | -165 | 63 | 0 |
| 30 Sep 22 | 18 | -175 | 63 | 105 |
| 30 Jun 22 | 12 | -176 | 61 | 0 |
| 31 Mar 22 | 9 | -171 | 60 | 0 |
| 31 Dec 21 | 6 | -158 | 57 | 0 |
| 30 Sep 21 | 6 | -156 | 56 | 0 |
| 30 Jun 21 | 6 | -149 | 54 | 0 |
| 31 Mar 21 | 4 | -140 | 50 | 0 |
| 31 Dec 20 | 4 | -130 | 46 | 0 |
| 30 Sep 20 | 3 | -123 | 43 | 0 |
| 30 Jun 20 | 2 | -127 | 41 | 0 |
| 31 Mar 20 | 2 | -138 | 41 | 0 |
| 31 Dec 19 | 1 | -137 | 43 | 0 |
| 30 Sep 19 | 2 | -144 | 43 | 0 |
| 30 Jun 19 | 42 | -99 | 43 | 0 |
| 31 Mar 19 | 51 | -102 | 44 | 0 |
| 31 Dec 18 | 60 | -96 | 44 | 0 |
| 30 Sep 18 | 62 | -87 | 42 | 0 |
| 30 Jun 18 | 49 | -93 | 39 | 0 |
| 31 Mar 18 | 43 | -69 | 36 | -19 |
| 31 Dec 17 | 38 | -70 | 31 | 0 |
| 30 Sep 17 | 42 | -58 | 29 | 17 |
| 30 Jun 17 | 17 | -76 | 26 | 32 |
| 31 Mar 17 | 14 | -78 | 24 | 68 |
| 31 Dec 16 | 14 | -72 | 23 | 0 |
| 30 Sep 16 | 10 | -73 | 23 | 63 |
| 30 Jun 16 | 12 | -61 | 21 | 57 |
| 31 Mar 16 | 15 | -55 | 21 | 48 |
| 31 Dec 15 | 14 | -48 | 18 | 40 |
| 30 Sep 15 | 13 | -19 | 14 | 29 |
| 30 Jun 15 | 10 | -37 | 10 | 24 |
Kaliteli Kazançlar: ADAP.Y şu anda kârlı değil.
Büyüyen Kar Marjı: ADAP.Y şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ADAP.Y kârlı değildir, ancak son 5 yılda zararlarını yılda 13.1% oranında azaltmıştır.
Büyüme Hızlandırma: ADAP.Y 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: ADAP.Y kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 54.5% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: ADAP.Y hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -244.01% ) sahiptir.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/18 01:10 |
| Gün Sonu Hisse Fiyatı | 2026/06/18 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Adaptimmune Therapeutics plc 8 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ying Huang | BofA Global Research |
| Mohit Bansal | Citigroup Inc |
| Reni Benjamin | Raymond James & Associates |